Risk Factors of Paraspinal Muscles in Degenerative Lumbar Spondylolisthesis

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-80
SponsorThe First People's Hospital of Yunnan

About this trial

This is a retrospectively observational study. The goal of this observational study is to analyze the risk factors of paraspinal muscles associated with the occurrence of spondylolisthesis in patients with degenerative lumbar spondylolisthesis(DLS) and to construct a predictive model. The main question it aims to answer is: Which paraspinal muscle changes are risk factors for DLS? We will collect the information of patients who have undergone lumbar MRI in our hospital and have been diagnosed with back pain ( including spondylolisthesis or no spondylolisthesis) during the period from 2022 to 2024.The collected data included gender, age, body mass index (BMI), diabetes, hypertension, occupation and imaging parameters. We will then retrospectively analyze the risk factors associated with lumbar spondylolisthesis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients who presented to our hospital with back pain(the diagnosis was spondylolisthesis or no spondylolisthesis);

Patients older than 50 years;

Patients with complete clinical data and magnetic resonance imaging (MRI) before surgery.

Disqualifiers

The patient has previous spinal surgery;

Patients with lumbar tumor,lumbar infection and lumbar tuberculosis;

Patients with incomplete MRI sequence.

Trial population

Patients who have undergone lumbar MRI in our hospital and have been diagnosed with back pain ( including spondylolisthesis or no spondylolisthesis) during the period from 2022 to 2024.

Trial design

Design model

Other

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups
Group A: Group A
Group B: Group B

Trial outcomes

Primary outcomes

1

the MF FCSA

The functional cross-sectional areas of the multifidus muscl.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels

Time frame
Two weeks before treatment
2

the ES FCSA

The functional cross-sectional areas of the erector spinae.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels

Time frame
Two weeks before treatment
3

the MF CSA

the total cross-sectional areas of the multifidus muscl.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels

Time frame
Two weeks before treatment
4

the ES CSA

the total cross-sectional areas of the erector spinae.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels

Time frame
Two weeks before treatment

Secondary outcomes

1

SMI

The skeletal muscle index.SMI = l CSA of muscle on an axial scan (expressed as cm2) divided by the square of the patient's height (expressed as cm2).

Time frame
Two weeks before treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: